Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab)
Open Access
- 17 November 2003
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 74 (4) , 263-267
- https://doi.org/10.1002/ajh.10413
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adultsBritish Journal of Haematology, 2002
- Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpuraBlood, 2001
- Sustained remission of platelet counts following monoclonal anti‐CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropeniaEuropean Journal of Haematology, 2001
- Morbidity and mortality in adults with idiopathic thrombocytopenic purpuraBlood, 2001
- Refractory autoimmune thrombocytopenic purpura treatment with RituximabAmerican Journal of Hematology, 2001
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphomaBlood, 2000
- Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpuraThe American Journal of Medicine, 1995
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURAThe Lancet, 1981
- Treatment of refractory thrombocytopenic purpura with cyclophosphamideAmerican Journal of Hematology, 1976
- RESULTS OF TREATMENT IN 71 PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURAThe Lancet Healthy Longevity, 1961